Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RT001 for Lateral Canthal Lines
NCT00884234Phase 2Completed
- Sponsor
- Revance Therapeutics
- Start
- Feb 2009
- Primary completion
- Apr 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lateral canthal rhytides comparing RT001 with Vehicle (2 arms). Primary endpoints: Investigator Global Assessment Improvement at Week 6 and Incidence of Treatment Emergent Adverse Events at Week 6. Started Feb 2009; status: completed.
02
Drugs
daxibotulinumtoxinA
03
Conditions
lateral canthal rhytides
Beyond the preview
Go deeper on NCT00884234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00884234.